These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 23648633)

  • 21. Intrinsic toxicity of glucose, due to non-enzymatic glycation, is controlled in-vivo by deglycation systems including: FN3K-mediated deglycation of fructosamines and transglycation of aldosamines.
    Szwergold BS
    Med Hypotheses; 2005; 65(2):337-48. PubMed ID: 15922110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The physiological substrates of fructosamine-3-kinase-related-protein (FN3KRP) are intermediates of nonenzymatic reactions between biological amines and ketose sugars (fructation products).
    Szwergold BS; Bunker RD; Loomes KM
    Med Hypotheses; 2011 Nov; 77(5):739-44. PubMed ID: 21924559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence That Differences in Fructosamine-3-Kinase Activity May Be Associated With the Glycation Gap in Human Diabetes.
    Dunmore SJ; Al-Derawi AS; Nayak AU; Narshi A; Nevill AM; Hellwig A; Majebi A; Kirkham P; Brown JE; Singh BM
    Diabetes; 2018 Jan; 67(1):131-136. PubMed ID: 29066600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzymatic deglycation--a new paradigm or an epiphenomenon?
    Szwergold BS; Beisswenger PJ
    Biochem Soc Trans; 2003 Dec; 31(Pt 6):1428-32. PubMed ID: 14641081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic variability of the fructosamine 3-kinase gene in diabetic patients.
    Mosca L; Penco S; Patrosso MC; Marocchi A; Lapolla A; Sartore G; Chilelli NC; Paleari R; Mosca A
    Clin Chem Lab Med; 2011 May; 49(5):803-8. PubMed ID: 21288167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fructosamine 3-kinase is involved in an intracellular deglycation pathway in human erythrocytes.
    Delpierre G; Collard F; Fortpied J; Van Schaftingen E
    Biochem J; 2002 Aug; 365(Pt 3):801-8. PubMed ID: 11975663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of fructosamine-3-kinase in protecting against the onset of microvascular and macrovascular complications in patients with T2DM.
    Sartore G; Ragazzi E; Burlina S; Paleari R; Chilelli NC; Mosca A; Avemaria F; Lapolla A
    BMJ Open Diabetes Res Care; 2020 May; 8(1):. PubMed ID: 32467223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of the genes for fructosamine-3-kinase and fructosamine-3-kinase-related protein appears to be constitutive and unaffected by environmental signals.
    Conner JR; Beisswenger PJ; Szwergold BS
    Biochem Biophys Res Commun; 2004 Oct; 323(3):932-6. PubMed ID: 15381090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnesium-dependent phosphatase-1 is a protein-fructosamine-6-phosphatase potentially involved in glycation repair.
    Fortpied J; Maliekal P; Vertommen D; Van Schaftingen E
    J Biol Chem; 2006 Jul; 281(27):18378-85. PubMed ID: 16670083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Hypothesis: Fructosamine-3-Kinase-Related-Protein (FN3KRP) Catalyzes Deglycation of Maillard Intermediates Directly Downstream from Fructosamines.
    Szwergold B
    Rejuvenation Res; 2021 Aug; 24(4):310-318. PubMed ID: 34314247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FN3K expression in COPD: a potential comorbidity factor for cardiovascular disease.
    Alderawi A; Caramori G; Baker EH; Hitchings AW; Rahman I; Rossios C; Adcock I; Cassolari P; Papi A; Ortega VE; Curtis JL; Dunmore S; Kirkham P
    BMJ Open Respir Res; 2020 Nov; 7(1):. PubMed ID: 33208304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transglycation--a potential new mechanism for deglycation of Schiff's bases.
    Szwergold BS; Howell SK; Beisswenger PJ
    Ann N Y Acad Sci; 2005 Jun; 1043():845-64. PubMed ID: 16037312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression of fructosamine 3 kinase in patients with colorectal cancer.
    Caruso MG; Notarnicola M; Altomare DF; Misciagna G
    Oncology; 2007; 73(1-2):72-5. PubMed ID: 18334852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low red blood cell levels of deglycating enzymes in colorectal cancer patients.
    Notarnicola M; Caruso MG; Tutino V; Guerra V; Misciagna G
    World J Gastroenterol; 2011 Jan; 17(3):329-33. PubMed ID: 21253391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The fructosamine 3-kinase knockout mouse: a tool for testing the glycation hypothesis of intracellular protein damage in diabetes and aging.
    Monnier VM
    Biochem J; 2006 Oct; 399(2):e11-3. PubMed ID: 16987105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening fructosamine-3-kinase (FN3K) inhibitors, a deglycating enzyme of oncogenic Nrf2: Human FN3K homology modelling, docking and molecular dynamics simulations.
    Beeraka NM; Zhang J; Mandal S; Vikram P R H; Liu J; B M N; Zhao D; Vishwanath P; B M G; Fan R
    PLoS One; 2023; 18(11):e0283705. PubMed ID: 37910519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Yeast-produced fructosamine-3-kinase retains mobility after ex vivo intravitreal injection in human and bovine eyes as determined by Fluorescence Correlation Spectroscopy.
    Minnaert AK; van Schie L; Grootaert H; Himpe J; Devos S; Weyts W; De Keersmaecker H; Braeckmans K; Van Aken E; Delanghe JR; De Smedt SC; Callewaert N; Remaut K
    Int J Pharm; 2022 Jun; 621():121772. PubMed ID: 35487399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A redox-active switch in fructosamine-3-kinases expands the regulatory repertoire of the protein kinase superfamily.
    Shrestha S; Katiyar S; Sanz-Rodriguez CE; Kemppinen NR; Kim HW; Kadirvelraj R; Panagos C; Keyhaninejad N; Colonna M; Chopra P; Byrne DP; Boons GJ; van der Knaap E; Eyers PA; Edison AS; Wood ZA; Kannan N
    Sci Signal; 2020 Jul; 13(639):. PubMed ID: 32636308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality.
    Tanhäuserová V; Kuricová K; Pácal L; Bartáková V; Rehořová J; Svojanovský J; Olšovský J; Bělobrádková J; Kaňková K
    Clin Chem Lab Med; 2014 Jan; 52(1):77-83. PubMed ID: 23492569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of liver function, antioxidant responses, insulin resistance and glucose transport by Oroxylum indicum stem bark in STZ induced diabetic rats.
    Singh J; Kakkar P
    Food Chem Toxicol; 2013 Dec; 62():722-31. PubMed ID: 24140466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.